Physician profile
Michael J App
NPI 1467490953
$12,705.17
in general payments reported to CMS, 2019-2025
69 companies · $1,916 in 2025
The $1,916 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,468 · 2020: $1,560 · 2021: $1,853 · 2022: $1,907 · 2023: $1,830 · 2024: $2,172 · 2025: $1,916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,851 · Education: $66.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,850.73 |
| Education | $66.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,639.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,537.43 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,263.83 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $1,070.88 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $640.69 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Lilly USA, LLC | $534.41 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Merck Sharp & Dohme LLC | $421.05 | 2019-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $416.34 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Astellas Pharma US INC | $350.19 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $334.09 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $256.31 | 2019-2024 | Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $251.92 | 2019-2024 | Rexulti, Abilify Maintena |
| Collegium Pharmaceutical, INC. | $225.78 | 2025 | Jornay Pm |
| Exact Sciences Corporation | $221.42 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $217.26 | 2019-2023 | Trintellix |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael App listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.